Clinical trial
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian…
NCT00316147 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00316147 |
|---|---|
| Title | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules |
| Official title | Phase IIIb, Open, Randomized, Multicenter Study to Assess the Immunogenicity & Safety of GSK Biologicals' Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants When Given at 6-10-14 Weeks of Age or at 2-4-6 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Acellular Pertussis, Tetanus, Haemophilus Influenzae Type b, Hepatitis B, Poliomyelitis |
| Intervention type | Biological |
| Interventions | DTPa-HBV-IPV/Hib vaccine |
| Enrollment | 224 |
| Start date | Dec 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Apr 20, 2006 |
| Last update posted | Sep 28, 2016 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: